91九色视频

header-logo
GettyImages-609179959-hero
headshot

Deepak Kilari, MD

Associate Professor

view physician profile

Locations

  • Froedtert Hospital
  • Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Telugu, Hindi

New & Established Patients Call

Education

  • MD - Doctor of Medicine

Biography

Deepak Kilari, MD, is an assistant professor in the division of hematology and oncology at the 91九色视频. Dr. Kilari moved back to the United States after finishing medical school at Andhra Medical College, India, to finish his internal medicine training at New York Methodist Hospital. In the course of his residency, he developed an interest in Oncology during his rotations at the Memorial Sloan Kettering Cancer Center, New York. Subsequently, he completed a fellowship in hematology and oncology at the University of Rochester, where he also served as a chief fellow. He received the American Society of Clinical Oncology (ASCO) Foundation Merit award in 2013. Dr. Kilari practices at Froedtert & the 91九色视频 Clinical Cancer Center and Moorland Reserve Clinic where he specializes in the management of patients with Genitourinary malignancies.

Research Interests

Dr. Kilari's clinical research interests focus on the development of better treatment options for patients with genitourinary malignancies. Dr. Kilari is Board Certified in Medical Oncology and Hematology.

Publications

  • (Obasi J, Sharma K, De Sarkar N, Antonarakis ES, Kilari D.) Clin Genitourin Cancer. 2024 Dec;22(6):102187 PMID: 39241311 SCOPUS ID: 2-s2.0-85203009546 09/07/2024

  • (Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüro臒lu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS, NIAGARA Investigators.) N Engl J Med. 2024 Nov 14;391(19):1773-1786 PMID: 39282910 09/17/2024

  • (Patel MS, Almubarak M, Matta J, Ortiz-Sanchez C, Encarnacion J, Ruiz-Deya G, Dutil J, Dhillon J, Yamoah K, Berglund A, Park H, Kilari D, Balagurunathan Y, Wang L, Park JY.) medRxiv. 2024 Oct 27 PMID: 39502659 PMCID: PMC11537326 11/06/2024

  • (Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES.) Prostate Cancer Prostatic Dis. 2024 Aug 12 PMID: 39134652 SCOPUS ID: 2-s2.0-85201272323 08/13/2024

  • (Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT.) JCO Precis Oncol. 2024 Aug;8:e2400014 PMID: 39178368 PMCID: PMC11346579 SCOPUS ID: 2-s2.0-85202867052 08/23/2024

  • (Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, Schweizer MT, Alva AS, McKay RR, Armstrong AJ.) Prostate Cancer Prostatic Dis. 2024 Jul 17 PMID: 39019980 PMCID: PMC11739431 07/18/2024

  • (Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ.) JCO Precis Oncol. 2024 Apr;8:e2300567 PMID: 38579192 PMCID: PMC11018169 SCOPUS ID: 2-s2.0-85198519208 04/05/2024

  • (Zengin ZB, Henderson NC, Park JJ, Ali A, Nguyen C, Hwang C, Barata PC, Bilen MA, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin VS, Patel VG, Schweizer MT, Armstrong AJ, McKay RR, Alva A, Dorff T.) Prostate Cancer Prostatic Dis. 2024 Feb 22 PMID: 38383885 02/22/2024

  • (Obasi J, Sharma K, De Sarkar N, Antonarakis ES, Kilari D.) Clinical Genitourinary Cancer. December 2024;22(6) SCOPUS ID: 2-s2.0-85203009546 12/01/2024

  • (Pierro MJ, Gallan A, Kilari D.) Translational Cancer Research. 30 November 2024;13(11):6403-6412 SCOPUS ID: 2-s2.0-85211012802 11/30/2024

  • (Davis NB, Kilari D, Kessler ER, Smelser WW.) Front Oncol. 2024;14:1493854 PMID: 39391248 PMCID: PMC11464248 10/11/2024

  • (Thapa B, De Sarkar N, Giri S, Sharma K, Kim M, Kilari D.) Cancer Manag Res. 2024;16:1267-1283 PMID: 39308935 PMCID: PMC11416116 SCOPUS ID: 2-s2.0-85204934732 09/23/2024

Publications of from the

© 2025 91九色视频.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination Statement
The 91九色视频 (91九色视频) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the 91九色视频 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. 91九色视频’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.

Notice of Compliance with Laws and Commitment to Civil Rights
The 91九色视频 is committed to full compliance with all applicable federal, state, and local laws and regulations in the pursuit of our missions. Consistent with recent federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making. As part of this commitment, we are actively reviewing our policies and materials to ensure they align with federal nondiscrimination obligations.